BETA-2-MICROGLOBULIN (B2M) AND NEOPTERIN (NEOP) LEVELS IN ADULT T-CELL LEUKEMIA/LYMPHOMA (ATL) (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


BETA-2-MICROGLOBULIN (B2M) AND NEOPTERIN (NEOP) LEVELS IN ADULT T-CELL LEUKEMIA/LYMPHOMA (ATL) (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 10:A23 1991. Unique Identifier : AIDSLINE ICDB/91671503
Giusti R; Manns A; Hanchard B; Cranston B; Murphy J; Murphy E; Williams E; Fuchs D; Blattner W; et al; NCI, Rockville, MD 20852

Abstract: Studies in endemic areas suggest a long latent period between HTLV-I infection and ATL with an estimated 3-4% cumulative lifetime risk of ATL among seropositives. The current study was undertaken to evaluate markers of immune activation in HTLV-I infection and disease. Serum B2M and NEOP levels were evaluated by radioimmunoassay in several Jamaican populations, including healthy individuals: 25 seronegative (HTLV -) and 25 seropositive (HTLV +); tropical spastic paraparesis (HAM/TSP) patients (pts; n=25); and ATL pts (n=25). Results are presented in a table. Among ATL pts, NEOP levels were correlated with total WBC count (r=0.66; p=0.005) and with percent lymphocytes (r=0.44; p=0.03). B2M levels were significantly correlated with serum calcium (r=0.48; p=0.02). NEOP and B2M may provide prognostic information in ATL pts and prospective studies may indicate viral activation in HTLV-I infected individuals.
Keywords: beta 2-Microglobulin/*ANALYSIS Biopterin/*ANALOGS & DERIVATIVES/BLOOD Calcium/BLOOD Human Jamaica Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/BLOOD/ *DIAGNOSIS Leukocyte Count Prognosis Prospective Studies Radioimmunoassay Tumor Markers, Biological/*BLOOD ABSTRACTKWDbeta2-microglobulin/KWDanalysisbiopterin/KWDanalogs&derivatives/bloodcalcium/bloodhumanjamaicaleukemia-lymphoma,t-cell,acute,htlv-i-associated/blood/KWDdiagnosisleukocytecountprognosisprospectivestudiesradioimmunoassaytumormarkers,biological/KWDbloodabstract
910930
M9190735

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .